1418. Current Epidemiology and Trends in Invasive Haemophilus influenzae Disease—United States, 2009–2014
Session: Poster Abstract Session: Public Health
Friday, October 28, 2016
Room: Poster Hall
Posters
  • SOETERS IDWeek 2016 poster Hi trends 102116.pdf (179.3 kB)
  • Background: Invasive Haemophilus influenzae disease can be caused by both encapsulated serotypes and nontypeable bacteria. We describe the epidemiology of invasive H. influenzae disease in the US during 2009–2014.

    Methods: Data were collected from active population- and laboratory-based surveillance for invasive H. influenzae disease conducted through Active Bacterial Core surveillance (ABCs) sites during 2009–2014. Isolates were serotyped via slide agglutination and real-time PCR. Case-fatality rates (CFR) were calculated using cases with known outcomes as the denominator. Incidence rates per 100,000 population were determined using US Census data; projected nationwide estimates were standardized for race and age.

    Results: During the surveillance period, ABCs sites reported 4,124 cases of invasive H. influenzae disease among all ages, resulting in an estimated national annual incidence of 1.9 cases per 100,000 population. Incidence was highest among children aged <5 years (6.5) and adults aged ≥65 years (6.4). The largest burden of disease among children aged <5 years was in infants aged <1 year (incidence: 8.8). Nearly half (47%) of disease among infants aged <1 year occurred during the first month of life, 71% of which occurred in preterm or low-birth weight infants. Among children aged <5 years, disease burden was substantially higher in American Indian and Alaska Natives (AI/AN) (incidence: 43.4) than in all other races combined (incidence: 5.8). The most common clinical syndromes were bacteremic pneumonia (62%) and bacteremia (26%); 7% had meningitis. Overall, 14% of cases were fatal; CFR was highest among adults aged ≥65 years (20%). Incidence and CFR were highest for nontypeable H. influenzae (incidence: 1.3; CFR: 16%) compared to non-b encapsulated serotypes (incidence: 0.6; CFR: 10%) and Hib (incidence: 0.04; CFR: 4%). Only 1.7% of invasive H. influenzae disease was due to Hib. Serotype f caused the majority (63%) of non-b encapsulated serotypes, with 20% due to serotype a, 17% serotype e, and 0.3% serotype d.

    Conclusion: A considerable burden of invasive H. influenzae disease still affects the oldest and youngest age groups, particularly AI/AN children. Nontypeable H. influenzae currently causes the highest morbidity and mortality.

    Heidi Soeters, PhD, MPH1,2, Amy Blain, MPH1, Brooke Doman, MPH3, Monica Farley, MD, FIDSA4, Lee Harrison, MD5, Ruth Lynfield, MD, FIDSA6, Lisa Miller, MD, MSPH7, Susan Petit, MPH8, Arthur Reingold, MD, FIDSA9, William Schaffner, MD, FIDSA, FSHEA10, Ann Thomas, MD, MPH11, Shelley M. Zansky, PhD12, Xin Wang, PhD1 and Elizabeth Briere, MD13, (1)National Center for Immunization and Respiratory Diseases, CDC, Atlanta, GA, (2)Epidemic Intelligence Service, CDC, Atlanta, GA, (3)New Mexico Department of Health, Sante Fe, NM, (4)Department of Medicine, Emory University School of Medicine and Atlanta VA Medical Center, Atlanta, GA, (5)John Hopkins Bloomberg School of Public Health, Baltimore, MD, (6)Minnesota Department of Health, St. Paul, MN, (7)Colorado Department of Public Health and Environment, Denver, CO, (8)Connecticut Department of Public Health, Hartford, CT, (9)University of California - Berkeley, Berkeley, CA, (10)Vanderbilt University School of Medicine, Nashville, TN, (11)Oregon Health Authority, Portland, OR, (12)New York State Department of Health, Albany, NY, (13)Meningitis and Vaccine Preventable Diseases, Centers for Disease Control and Prevention, Atlanta, GA

    Disclosures:

    H. Soeters, None

    A. Blain, None

    B. Doman, None

    M. Farley, None

    L. Harrison, None

    R. Lynfield, None

    L. Miller, None

    S. Petit, None

    A. Reingold, None

    W. Schaffner, None

    A. Thomas, None

    S. M. Zansky, None

    X. Wang, None

    E. Briere, None

    See more of: Public Health
    See more of: Poster Abstract Session

    Findings in the abstracts are embargoed until 12:01 a.m. CDT, Wednesday Oct. 26th with the exception of research findings presented at the IDWeek press conferences.